论文部分内容阅读
目的 分析与探讨呼出气一氧化氮水平在小儿支气管哮喘疾病中的表达,并研究其对疾病诊疗的应用价值.方法 将2016年11月—2017年11月来检查的儿童选为研究病例,经相关检查后确诊的67 例支气管哮喘患儿为观察组,随机选取33 名健康儿童为对照组,比较两组呼出气一氧化氮测定结果及肺功能情况.观察组支气管哮喘儿童经过β2受体激动剂及糖皮质激素系统治疗后,观察并评价其治疗1、3、6 个月后,不同疾病控制期的呼出气一氧化氮测定结果及肺功能情况.结果 观察组支气管哮喘儿童呼出气一氧化氮测定值[(95.54±12.37)PPb]高于对照组[(16.72±5.28)PPb],FEV%测定值[(51.84±9.77)%]低于对照组[(84.97±20.18)%],差异有统计学意义(P＜0.05).经过治疗后,观察组治疗1、3、6 个月后肺功能FEV%测定值[(62.89±8.66)%、(71.18±8.75)%、(82.93±8.21)%],呼出气一氧化氮测定值[(66.42±9.11)PPb、(42.55±9.34)PPb、(18.67±5.97)PPb]均优于治疗前FEV%测定值[(51.84±9.77)%]、呼出气一氧化氮测定值[(95.54±12.37) PPb],差异有统计学意义(P＜0.05).观察组治疗3、6 个月后肺功能及呼出气一氧化氮测定值均优于治疗1 个月后,差异有统计学意义(P＜0.05).观察组治疗6 个月后肺功能及呼出气一氧化氮测定值均优于治疗3 个月后,差异有统计学意义(P＜0.05).结论 呼出气一氧化氮测定结果与小儿支气管哮喘的疾病表达相关,有助于疾病的诊断,且随着支气管哮喘疾病的控制,呼出气一氧化氮测定结果逐渐降低,可以评价气道炎症的严重程度,对疾病的诊断及治疗效果具有较优的指导价值,有助于病情严重程度的监测,临床应用价值较高.“,”Objective To analyze and explore the expression of exhaled nitric oxide in diagnosis and treatment of pediatric bronchial asthma, and to study its application effect in disease diagnosis and treatment. Methods The children who were tested in our hospital from November 2016 to November 2017 were selected as the research subjects, and 67 cases bronchial asthma patients diagnosed with relevant examination were selected as the observation group, and another 33 healthy children were randomly selected as the control group. The exhaled nitric oxide detection results and lung function of two groups were compared. The bronchial asthma patients in the observation group were given β2 receptor agonists and glucocorticoid system therapy, and the exhaled nitric oxide detection results and lung function in different disease control period after treated for 1, 3 and 6 months were observed and evaluated. Results The exhaled nitric oxide measured value (95.54±12.37) PPb in the observation group was higher than (16.72±5.28) PPb in the control group, and the FEV% measured value (51.84±9.77) % in the observation group was lower than (84.97±20.18) % in the control group, and the differences were statistically significant (P＜0.05). The lung function FEV% measured value[ (62.89±8.66) %, (71.18±8.75) %, (82.93±8.21) %] and the exhaled nitric oxide measured value[ (66.42±9.11) PPb, (42.55±9.34) PPb, (18.67±5.97) PPb] after treated for 1, 3, and 6 months in the observation group were better than those in the control group [FEV% measured value (51.84±9.77) % and exhaled nitric oxide measured value (95.54±12.37) PPb], and the differences were statistically significant (P＜0.05). The exhaled nitric oxide measured value in the observation group after treated for 3 and 6 months was better than that after treated for 1 month, and the difference was statistically significant (P＜0.05). The exhaled nitric oxide measured value in the observation group after treated for 6 months was better than that after treated for 3 months, and the difference was statistically significant (P＜0.05). Conclusion The exhaled nitric oxide detection results are associated with the disease expression of bronchial asthma, which are contributed to the diagnosis of the disease. With the control of bronchial asthma disease, the exhaled nitric oxide detection results are gradually reduced, which can be used to evaluate the severity of airway, and has better guide value to the diagnosis and treatment of disease. It is contributed to the monitoring of the severity of the disease, and has higher clinical application value.